Franckena Martine, Stalpers Lukas J A, Koper Peter C M, Wiggenraad Ruud G J, Hoogenraad Wim J, van Dijk Jan D P, Wárlám-Rodenhuis Carla C, Jobsen Jan J, van Rhoon Gerard C, van der Zee Jacoba
Department of Radiation Oncology, Hyperthermia Unit, Erasmus Medical Center Rotterdam, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1176-82. doi: 10.1016/j.ijrobp.2007.07.2348. Epub 2007 Sep 19.
The local failure rate in patients with locoregionally advanced cervical cancer is 41-72% after radiotherapy (RT) alone, whereas local control is a prerequisite for cure. The Dutch Deep Hyperthermia Trial showed that combining RT with hyperthermia (HT) improved 3-year local control rates of 41-61%, as we reported earlier. In this study, we evaluate long-term results of the Dutch Deep Hyperthermia Trial after 12 years of follow-up.
From 1990 to 1996, a total of 114 women with locoregionally advanced cervical carcinoma were randomly assigned to RT or RT+HT. The RT was applied to a median total dose of 68 Gy. The HT was given once weekly. The primary end point was local control. Secondary end points were overall survival and late toxicity.
At the 12-year follow-up, local control remained better in the RT+HT group (37% vs. 56%; p=0.01). Survival was persistently better after 12 years: 20% (RT) and 37% (RT+HT; p=0.03). World Health Organization (WHO) performance status was a significant prognostic factor for local control. The WHO performance status, International Federation of Gynaecology and Obstetrics (FIGO) stage, and tumor diameter were significant for survival. The benefit of HT remained significant after correction for these factors. European Organization for Research and Treatment of Cancer Grade 3 or higher radiation-induced late toxicities were similar in both groups.
For locoregionally advanced cervical cancer, the addition of HT to RT resulted in long-term major improvement in local control and survival without increasing late toxicity. This combined treatment should be considered for patients who are unfit to receive chemotherapy. For other patients, the optimal treatment strategy is the subject of ongoing research.
局部区域晚期宫颈癌患者单纯放疗(RT)后的局部失败率为41%-72%,而局部控制是治愈的前提条件。如我们之前报道的,荷兰深部热疗试验表明,放疗联合热疗(HT)可将3年局部控制率提高至41%-61%。在本研究中,我们评估了荷兰深部热疗试验12年随访后的长期结果。
1990年至1996年,共有114例局部区域晚期宫颈癌女性患者被随机分配至单纯放疗组或放疗联合热疗组。放疗的中位总剂量为68 Gy。热疗每周进行一次。主要终点为局部控制。次要终点为总生存期和晚期毒性。
在12年随访时,放疗联合热疗组的局部控制情况仍更好(37%对56%;p=0.01)。12年后的生存期也持续更好:20%(单纯放疗组)和37%(放疗联合热疗组;p=0.03)。世界卫生组织(WHO)体能状态是局部控制的显著预后因素。WHO体能状态、国际妇产科联盟(FIGO)分期和肿瘤直径对生存期有显著影响。校正这些因素后,热疗的益处仍然显著。两组的欧洲癌症研究与治疗组织3级或更高等级的放射性晚期毒性相似。
对于局部区域晚期宫颈癌,放疗联合热疗可在不增加晚期毒性的情况下,使局部控制和生存期得到长期显著改善。对于不适合接受化疗的患者,应考虑这种联合治疗。对于其他患者,最佳治疗策略仍是正在进行的研究课题。